Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03447314 · ClinicalTrials.gov registry record · Phase 1
Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid Tumors
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
NCT03447314 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 54 participants.
The verdict
NCT03447314, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
Study Summary
GSK1795091 is being developed for administration in combination with other immune system modulators for the treatment of cancers. The study will be conducted in two parts. In Part 1, dose escalation will be performed to identify combination dose levels comprising GSK1795091 with either 24 milligrams (mg) GSK3174998 (Part 1a), 80 mg GSK3359609 (Part 1b), or 200 mg pembrolizumab (Part 1c). One dose level of GSK3174998, GSK3359609, or pembrolizumab with up to 5 dose levels of GSK1795091 are planned for evaluation. In Part 2 (dose-expansion), subjects will receive a single dose level of GSK1795091 as identified based on data from Part 1, in combination with either GSK3174998, GSK3359609, or pembrolizumab.
Interventions
- DRUG Pembrolizumab
- DRUG GSK3174998
- DRUG GSK1795091
- DRUG GSK3359609
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2018-03-26 |
| Est. Completion | 2022-03-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03447314
The ClinicalTrials.gov registry entry for NCT03447314 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT03447314 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03447314 about?
NCT03447314 is a clinical study titled "Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid Tumors". GSK1795091 is being developed for administration in combination with other immune system modulators for the treatment of cancers. The study will be conducted in two parts. In Part 1, dose escalation will be performed to identify combination dose levels comprising GSK1795091 with either 24 milligrams...
What is the current status of trial NCT03447314?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2018-03-26. Estimated completion is 2022-03-11.
What interventions are being tested in trial NCT03447314?
The interventions under investigation include: Pembrolizumab (DRUG), GSK3174998 (DRUG), GSK1795091 (DRUG), GSK3359609 (DRUG).
Who is sponsoring clinical trial NCT03447314?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.